Enzene Biosciences Ltd.

Traditional biologics manufacturing relies on batch processing, which involves sequential operations and faces significant limitations, such as low productivity, lengthy processing times, and high operational costs due to large infrastructure needs and frequent manual interventions. To overcome these challenges, Enzene has introduced a commercially validated, fully-connected continuous manufacturing platform (FCCM) for protein-based therapeutics. This platform, EnzeneX™, operates continuously from upstream to downstream, enhancing productivity with a smaller facility footprint. It achieves higher cell densities and viabilities, resulting in up to ten times greater productivity than traditional methods. EnzeneX™ 2.0 aims to reduce mAb production costs to less than $40 per gram, making life-saving medicines more affordable and accessible globally.